We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Provention Bio Inc
15 own
12 watching
Current Price
$0
$-0.29
(-3.04%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
817.44M
52-Week High
10.88
52-Week Low
3.185
Average Volume
1.42M
Dividend Yield
--
P/E Ratio
--
Market Capitalization817.44M52-Week High10.8852-Week Low3.185Average Volume1.42MDividend Yield--P/E Ratio--What does the Provention Bio Inc do?
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease. Provention Bio, Inc. was incorporated in 2016 and is based in Oldwick, New Jersey.
Read More
How much money does Provention Bio Inc make?
News & Events about Provention Bio Inc.
Zolmax
16days ago
Provention Bio, Inc. (NASDAQ:PRVB Get Rating) major shareholder Sessa Capital (Master), L.P. sold 3,000,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $9.40, for a total transaction of $28,200,000.00. Following...
Ticker Report
1month ago
Provention Bio, Inc. (NASDAQ:PRVB Get Rating) insider Francisco Leon sold 187,000 shares of Provention Bio stock in a transaction on Thursday, December 29th. The shares were sold at an average price of $10.26, for a total value of $1,918,620.00. Following the sale, the insider now directly ...
Zolmax
2 months ago
Provention Bio, Inc. (NASDAQ:PRVB Get Rating) has earned a consensus rating of Buy from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages ...
Benzinga
2 months ago
Latest Ratings for PRVB
DateFirmActionFromTo Aug 2021OppenheimerMaintainsOutperform Aug 2021HC Wainwright & Co.MaintainsBuy Apr 2021Chardan CapitalMaintainsBuy
View More Analyst Ratings for PRVB
View the Latest Analyst Ratings
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Provention Bio Inc share price today?
Can Indians buy Provention Bio Inc shares?
How can I buy Provention Bio Inc shares from India?
Can Fractional shares of Provention Bio Inc be purchased?
What are the documents required to start investing in Provention Bio Inc stocks?
What is today’s traded volume of Provention Bio Inc?
What is today’s market capitalisation of Provention Bio Inc?
What is the 52-Week High and Low Range of Provention Bio Inc?
What percentage is Provention Bio Inc down from its 52-Week High?
What percentage is Provention Bio Inc up from its 52-Week Low?
Current Price
$0
$-0.29
(-3.04%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.